Multivariate analyses of a 7-SNP–based classifier and clinicopathological characteristics associated with PFS and OS
| Variables . | Training cohort . | Internal validation cohort . | External validation cohort 1 . | External validation cohort 2 . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| PFS | ||||||||
| Age (≤60 vs >60 y) | 1.956 (1.307-2.927) | .001 | 2.222 (1.131-4.365) | .021 | 2.150 (1.284-3.600) | .004 | 2.165 (1.244-3.767) | .006 |
| B symptoms (no vs yes) | — | — | 1.831 (1.065-3.147) | .029 | — | — | — | — |
| ECOG-PS (0-1 vs ≥2) | — | — | — | — | — | — | 2.835 (1.038-3.245) | .037 |
| Ann Arbor stage (I-II vs III-IV) | 2.102 (1.513-2.921) | <.001 | 1.833 (1.024-3.284) | .042 | 2.385 (1.491-3.814) | <.001 | 2.441 (1.386-4.301) | .002 |
| Lymphoma node involvement (none or regional vs distant) | 2.146 (1.394-3.305) | .001 | 2.061 (1.047-4.058) | .036 | — | — | 2.069 (1.089-3.929) | .026 |
| Nonnasal type (no vs yes) | 1.612 (1.104-2.353) | .013 | — | — | — | — | — | — |
| LDH (normal vs elevated) | 1.702 (1.246-2.325) | .001 | 2.057 (1.202-3.520) | .009 | — | — | — | — |
| 7-SNP–based classifier (low risk vs high risk) | 3.261 (2.335-4.555) | <.001 | 3.562 (1.908-6.649) | <.001 | 3.496 (2.115-5.781) | <.001 | 4.510 (2.449-8.305) | <.001 |
| OS | ||||||||
| Age (≤60 vs >60 y) | 2.143 (1.407-3.265) | <.001 | 2.450 (1.246-4.818) | .009 | 2.183 (1.262-3.776) | .005 | 2.231 (1.223-4.069) | .009 |
| B symptoms (no vs yes) | 1.335 (0.966-1.846) | .080 | — | — | — | — | — | — |
| ECOG-PS (0-1 vs ≥2) | — | — | — | — | — | — | 2.012 (1.120-3.615) | .019 |
| Ann Arbor stage (I-II vs III-IV) | 2.035 (1.437-2.884) | <.001 | 1.935 (1.041-3.596) | .037 | 1.994 (1.109-3.585) | .021 | 2.354 (1.260-4.399) | .007 |
| Lymphoma node involvement (none or regional vs distant) | 2.387 (1.531-3.722) | <.001 | 2.231 (1.131-4.399) | .021 | — | — | 1.929 (0.956-3.899) | .046 |
| Nonnasal type (no vs yes) | 1.787 (1.210-2.641) | .004 | — | — | — | — | — | — |
| Extranodal involvement (0-1 vs ≥2 nodes) | — | — | — | — | 1.879 (1.046-3.374) | .035 | — | — |
| LDH (normal vs elevated) | 1.718 (1.234-2.391) | .001 | 1.881 (1.075-3.292) | .027 | — | — | — | — |
| 7-SNP–based classifier (low risk vs high risk) | 3.822 (2.646-5.520) | <.001 | 3.296 (1.740-6.246) | <.001 | 3.690 (2.113-6.444) | <.001 | 3.144 (1.677-5.893) | <.001 |
| Variables . | Training cohort . | Internal validation cohort . | External validation cohort 1 . | External validation cohort 2 . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| PFS | ||||||||
| Age (≤60 vs >60 y) | 1.956 (1.307-2.927) | .001 | 2.222 (1.131-4.365) | .021 | 2.150 (1.284-3.600) | .004 | 2.165 (1.244-3.767) | .006 |
| B symptoms (no vs yes) | — | — | 1.831 (1.065-3.147) | .029 | — | — | — | — |
| ECOG-PS (0-1 vs ≥2) | — | — | — | — | — | — | 2.835 (1.038-3.245) | .037 |
| Ann Arbor stage (I-II vs III-IV) | 2.102 (1.513-2.921) | <.001 | 1.833 (1.024-3.284) | .042 | 2.385 (1.491-3.814) | <.001 | 2.441 (1.386-4.301) | .002 |
| Lymphoma node involvement (none or regional vs distant) | 2.146 (1.394-3.305) | .001 | 2.061 (1.047-4.058) | .036 | — | — | 2.069 (1.089-3.929) | .026 |
| Nonnasal type (no vs yes) | 1.612 (1.104-2.353) | .013 | — | — | — | — | — | — |
| LDH (normal vs elevated) | 1.702 (1.246-2.325) | .001 | 2.057 (1.202-3.520) | .009 | — | — | — | — |
| 7-SNP–based classifier (low risk vs high risk) | 3.261 (2.335-4.555) | <.001 | 3.562 (1.908-6.649) | <.001 | 3.496 (2.115-5.781) | <.001 | 4.510 (2.449-8.305) | <.001 |
| OS | ||||||||
| Age (≤60 vs >60 y) | 2.143 (1.407-3.265) | <.001 | 2.450 (1.246-4.818) | .009 | 2.183 (1.262-3.776) | .005 | 2.231 (1.223-4.069) | .009 |
| B symptoms (no vs yes) | 1.335 (0.966-1.846) | .080 | — | — | — | — | — | — |
| ECOG-PS (0-1 vs ≥2) | — | — | — | — | — | — | 2.012 (1.120-3.615) | .019 |
| Ann Arbor stage (I-II vs III-IV) | 2.035 (1.437-2.884) | <.001 | 1.935 (1.041-3.596) | .037 | 1.994 (1.109-3.585) | .021 | 2.354 (1.260-4.399) | .007 |
| Lymphoma node involvement (none or regional vs distant) | 2.387 (1.531-3.722) | <.001 | 2.231 (1.131-4.399) | .021 | — | — | 1.929 (0.956-3.899) | .046 |
| Nonnasal type (no vs yes) | 1.787 (1.210-2.641) | .004 | — | — | — | — | — | — |
| Extranodal involvement (0-1 vs ≥2 nodes) | — | — | — | — | 1.879 (1.046-3.374) | .035 | — | — |
| LDH (normal vs elevated) | 1.718 (1.234-2.391) | .001 | 1.881 (1.075-3.292) | .027 | — | — | — | — |
| 7-SNP–based classifier (low risk vs high risk) | 3.822 (2.646-5.520) | <.001 | 3.296 (1.740-6.246) | <.001 | 3.690 (2.113-6.444) | <.001 | 3.144 (1.677-5.893) | <.001 |